» Articles » PMID: 36175866

Nanoengineering Facilitating the Target Mission: Targeted Extracellular Vesicles Delivery Systems Design

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2022 Sep 29
PMID 36175866
Authors
Affiliations
Soon will be listed here.
Abstract

Precision medicine has put forward the proposition of "precision targeting" for modern drug delivery systems. Inspired by techniques from biology, pharmaceutical sciences, and nanoengineering, numerous targeted drug delivery systems have been developed in recent decades. But the large-scale applications of these systems are limited due to unsatisfactory targeting efficiency, cytotoxicity, easy removability, and instability. As such, the natural endogenous cargo delivery vehicle-extracellular vesicles (EVs)-have sparked significant interest for its unique inherent targeting properties, biocompatibility, transmembrane ability, and circulatory stability. The membranes of EVs are enriched for receptors or ligands that interact with target cells, which endows them with inherent targeting mission. However, most of the natural therapeutic EVs face the fate of being cleared by macrophages, resulting in off-target. Therefore, the specificity of natural EVs delivery systems urgently needs to be further improved. In this review, we comprehensively summarize the inherent homing mechanisms of EVs and the effects of the donor cell source and administration route on targeting specificity. We then go over nanoengineering techniques that modify EVs for improving specific targeting, such as source cell alteration and modification of EVs surface. We also highlight the auxiliary strategies to enhance specificity by changing the external environment, such as magnetic and photothermal. Furthermore, contemporary issues such as the lack of a gold standard for assessing targeting efficiency are discussed. This review will provide new insights into the development of precision medicine delivery systems.

Citing Articles

Extracellular vesicle therapeutics for cardiac repair.

Hu Y, Zhang W, Ali S, Takeda K, Vahl T, Zhu D J Mol Cell Cardiol. 2024; 199:12-32.

PMID: 39603560 PMC: 11788051. DOI: 10.1016/j.yjmcc.2024.11.005.


Extracellular vesicles derived from endothelial progenitor cells modified by Houshiheisan promote angiogenesis and attenuate cerebral ischemic injury via miR-126/PIK3R2.

Zhang Y, Yang Q, Cheng H, Zhang Y, Xie Y, Zhang Q Sci Rep. 2024; 14(1):28166.

PMID: 39548169 PMC: 11568282. DOI: 10.1038/s41598-024-78717-4.


SMARTINI3 parametrization of multi-scale membrane models via unsupervised learning methods.

Soleimani A, Risselada H Sci Rep. 2024; 14(1):25714.

PMID: 39468134 PMC: 11519956. DOI: 10.1038/s41598-024-75490-2.


Biomimetic Nanoparticles for Basic Drug Delivery.

Tikhonov A, Kachanov A, Yudaeva A, Danilik O, Ponomareva N, Karandashov I Pharmaceutics. 2024; 16(10).

PMID: 39458635 PMC: 11510494. DOI: 10.3390/pharmaceutics16101306.


Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury.

Han D, Wang F, Shen D Theranostics. 2024; 14(13):5336-5370.

PMID: 39267789 PMC: 11388064. DOI: 10.7150/thno.99961.


References
1.
Han Q, Xie Q, Li F, Cheng Y, Wu T, Zhang Y . Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. Theranostics. 2021; 11(13):6526-6541. PMC: 8120217. DOI: 10.7150/thno.53886. View

2.
Nemeth K, Varga Z, Lenzinger D, Visnovitz T, Koncz A, Hegedus N . Extracellular vesicle release and uptake by the liver under normo- and hyperlipidemia. Cell Mol Life Sci. 2021; 78(23):7589-7604. PMC: 8629784. DOI: 10.1007/s00018-021-03969-6. View

3.
Rana S, Yue S, Stadel D, Zoller M . Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012; 44(9):1574-84. DOI: 10.1016/j.biocel.2012.06.018. View

4.
Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang J . Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2019; 28(2):536-547. PMC: 7001084. DOI: 10.1016/j.ymthe.2019.11.020. View

5.
Thakur A, Qiu G, Xu C, Han X, Yang T, Ng S . Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci Adv. 2020; 6(26):eaaz6119. PMC: 7319757. DOI: 10.1126/sciadv.aaz6119. View